Amelioration of neutrophil membrane function underlies granulocyte-colony stimulating factor action in glycogen storage disease 1b.
Glycogen storage disease (GSD) 1b is a metabolic disorder characterized by a deficiency of glucose 6-phosphate transporter and neutrophil alterations, which are reduced in number and functionally impaired. The present study aimed at investigating neutrophil dysfunction correlating submembrane and cytoskeletal changes at different ages with or without granulocyte-colony stimulating factor (G-CSF) treatment. GSD1b neutrophils showed reduced expression and diffused localization of focal adhesion kinase (FAK) and actin. No abnormalities were observed in GSD1a patient neutrophils. Gelsolin was also slightly reduced in neutrophils of GSD1b patients. When patients were treated for at least 3 months with G-CSF, the neutrophil number and the expression of FAK and actin were significantly increased. Granulocyte colony-stimulating factor treatment was similarly effective when performed in 1 year old patients. FAK auto- and IL-8-mediated phosphorylations were already affected as early as 1 year of age. G-CSF treatment also improved this alteration. Our data suggest that neutrophil dysfunction in GSD1b patients might be related to functional impairment and disorganization of proteins of the sub-membrane apparatus, and that G-CSF treatment counteracts neutropenia and prevents the progressive alterations of neutrophil sub-membrane proteins.
Lesma
E
E
Pharmacological Laboratories and Department of Medicine, Surgery and Dentistry, School of Medicine, University of Milano, Italy.
Riva
E
E
Giovannini
M
M
Di Giulio
A M
AM
Gorio
A
A
D000199:Actins / Q000096:biosynthesis; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001786:Blood Glucose / Q000032:analysis; D002462:Cell Membrane / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; D005953:Glycogen Storage Disease Type I / Q000097:blood* / Q000188:drug therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D019344:Lactic Acid / Q000032:analysis; D007958:Leukocyte Count; D009503:Neutropenia / Q000097:blood / Q000517:prevention & control*; D009504:Neutrophils / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000199:Actins; D001786:Blood Glucose; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D019344:Lactic Acid; D011505:Protein-Tyrosine Kinases; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; C496050:PTK2 protein, human